Neoadjuvant SBRT in Localized Advanced HNSCC

Head and Neck Squamous Carcinoma Clinical Trial

Official title:

Neoadjuvant Stereotactic Body Radiotherapy（SBRT）Combined With Immunotherapy for Locally Advanced Head and Neck Squamous Cell Carcinoma

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT06306846
• Other study ID #: 11235794
• Status: Recruiting
• Phase: Phase 2
• Start date: October 1, 2023
• Est. completion date: December 31, 2026

Study information

• Verified date: March 2024
• Source: Zhejiang Cancer Hospital
• Contact: Feng Jiang, MD
• Phone: 0086-571-88128202
• Email: jiangfeng[@]zjcc.org.cn
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The response rate of HNSCC to immune checkpoint blockade was not satisfied. Improving the mPR rate of neoadjuvant immunotherapy through the combination with other treatment methods is an important way to further improve the prognosis of such patients. This study aims to explore the efficacy and safety of PD-1 monoclonal antibody with neoadjvant SBRT and chemotherapy. The triple mode not only can Increase the effectiveness of neoadjuvant therapy，meanwhile，the in situ tumor vaccine inoculation effect generated by enhancing the release of specific antigens after tumor radiotherapy with PD-1 monoclonal antibody achieves a sustained anti-tumor immune effect throughout the body， reducing postoperative adjuvant radiotherapy and chemotherapy. The triple mode has important exploratory value in achieving high quality and long-term survival for patients, and may provides a more efficient mode for locally advanced HNSCC.

Description:

locally advanced HNSCC patients would receive PD-1 antibody and chemotherapy with or without SBRT covering GTV of primary disease and metastatic nodes , followed by surgery. pathological response was measured .Neoadjuvant PD-1 antibody and chemotherapy with certuxmab was also tested

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 81
• Est. completion date: December 31, 2026
• Est. primary completion date: December 31, 2026
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 70 Years

Eligibility

Inclusion Criteria:

1. Pathologically confirmed initially resectable Localized advanced head and neck squamous cell carcinoma,and plan for surgical resection.

2. Immunohistochemical confirmed the HPV status through P16 immunostaining.

3. Male or female, Between the aged from 18 to 70 years,

4. Able to provide informed consent, comply with agreements, and sign research specific consent documents.

5. ZPS is less than 2.

6. Adequate bone marrow, liver and kidney, heart , lung and other physiological function determined by Researchers, able to tolerate neoadjuvant anti-PD-1, anti-EGFR, and radiation therapy.

7. Subjects are willing and able to comply with visits, treatment regimens, laboratory tests, and other requirements of the study as spe.

Exclusion Criteria:

1. Any clinical illness, such as hemorrhage, active infection, or mental illness, that can hinder safe participation or adherence of research procedures.

2. Patients who cannot accept radiotherapy in standard treatment.

3. Long term maintenance of oral steroids (= 20mg prednisone equivalent per day) is required, excluding patients with inhaled, local, or non absorbable steroids.

4. Autoimmune diseases, including but not limited to inflammatory bowel disease, rheumatoid arthritis, autoimmune hepatitis, systemic sclerosis (scleroderma and variants), systemic lupus erythematosus, autoimmune vasculitis, autoimmune neuropathy (such as Guillain Barre syndrome), etc.

Related Conditions & MeSH terms

• Carcinoma
• Carcinoma, Squamous Cell
• Head and Neck Squamous Carcinoma

Intervention

Radiation:
• SBRT+immunochemotherpy
SBRT radiotherapy,followed with PD-1 monoclonal antibody and TP chemotherapy

Drug:
• Immunochemotherapy
PD-1 monoclonal antibody and TP chemotheapy
• cetuximab+immunochemotharpy
PD-1 monoclonal antibody and TP chemotheapy combined with cetuximab

Locations

Country	Name	City	State
China	Zhejiang Cancer Hospital	Hangzhou	Zhejiang

Sponsors (1)

Lead Sponsor	Collaborator
Jiang Feng

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	major pathology response (MPR)	major pathology response	4-6 weeks after the end of the neoadjuvant therapy